Saturday - November 23, 2024
AstraZeneca: Tezspire Met Both Co-Primary Endpoints in the Phase III Waypoint Trial in Patients With Chronic Rhinosinusitis With Nasal Polyps
November 09, 2024
WILMINGTON, Delaware, Nov. 9 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo

* * *

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZe . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products